Summary
Abbott Laboratories (ABT) filed an 8-K on October 17, 2012, to announce its third-quarter 2012 financial results. The filing primarily serves to furnish a press release detailing these results, which includes the use of non-GAAP financial measures. These non-GAAP figures are presented to offer investors a clearer view of ongoing business performance by excluding unusual or unpredictable items such as acquisition and separation costs, litigation reserves, R&D impairments, and restructuring charges. Management utilizes these non-GAAP measures internally for performance monitoring and believes they provide valuable insights for investors. However, the company emphasizes that these measures should be considered alongside, and not as a substitute for, traditional GAAP financial reporting. Investors should refer to the furnished press release for the specific financial details and reconciliations.
Key Highlights
- 1Abbott Laboratories announced its third-quarter 2012 financial results via an 8-K filing.
- 2The filing primarily furnished a press release containing the Q3 2012 earnings announcement.
- 3Abbott utilized non-GAAP financial measures, including adjusted net earnings and diluted earnings per share, in its Q3 reporting.
- 4These non-GAAP measures exclude items such as acquisition-related costs, separation costs, litigation reserves, R&D impairments, and restructuring charges.
- 5Management believes these non-GAAP metrics offer a better evaluation of ongoing business performance.
- 6Investors are advised to consider non-GAAP measures in conjunction with, not as a replacement for, GAAP financial measures.
- 7The press release is included as Exhibit 99.1 to the 8-K filing.